Jonathan Havens, Partner at Saul Ewing LLP, will speak on a panel, alongside four other professionals, at Cannabis Europa London 2026, being held May 26-27, 2026. Their topic will be "Schedule III and Beyond: What a Maturing US Federal Cannabis Framework Means for the International Market."
After decades of federal inaction, the United States is beginning to construct a coherent regulatory framework for cannabis, and the shape it is taking has implications on both sides of the Atlantic. The proposed rescheduling of cannabis to Schedule III would formally recognize its medical value under federal law for the first time, opening new research pathways and restructuring the tax environment for operators. Separately, recent legislative changes to the federal definition of hemp, which seek to close the regulatory loophole that allowed largely unregulated intoxicating products to proliferate outside any proper framework, signal a broader move toward bringing the entire cannabinoid category under meaningful federal oversight. This session asks what that process looks like from an international perspective. As the US works through the practical and political complexity of federal cannabis reform, are there lessons for European companies navigating their own frameworks? Where do transatlantic research, manufacturing and investment relationships go from here? And as markets mature, what does genuine regulatory convergence, or divergence, mean for businesses operating across borders?
Saul Ewing is a proud sponsor of this event.
